These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 11764962)
1. Structure toxicity relationships--how useful are they in predicting toxicities of new drugs? Nelson SD Adv Exp Med Biol; 2001; 500():33-43. PubMed ID: 11764962 [TBL] [Abstract][Full Text] [Related]
2. Avoiding hepatic injury from drugs. Kaplowitz N Gastroenterology; 1999 Oct; 117(4):759. PubMed ID: 10500055 [No Abstract] [Full Text] [Related]
3. Drug-induced hepatotoxicity. Lee WM N Engl J Med; 2003 Jul; 349(5):474-85. PubMed ID: 12890847 [No Abstract] [Full Text] [Related]
4. Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen AJ Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645 [TBL] [Abstract][Full Text] [Related]
5. How can 'Hy's law' help the clinician? Senior JR Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):235-9. PubMed ID: 16552792 [No Abstract] [Full Text] [Related]
6. Serious liver injury. Leading reason for drug removals, restrictions. Meadows M FDA Consum; 2001; 35(3):8-9. PubMed ID: 11458559 [No Abstract] [Full Text] [Related]
7. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Plosker GL; Faulds D Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691 [TBL] [Abstract][Full Text] [Related]
12. On the need for outcome trials in preventive pharmacology. Lessons from the recent experience with adverse drug reactions. Stern MP Diabetes Care; 1999 May; 22(5):844-5. PubMed ID: 10332692 [No Abstract] [Full Text] [Related]
13. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Johnson MD; Campbell LK; Campbell RK Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065 [TBL] [Abstract][Full Text] [Related]
14. Lessons from the glitazones: a story of drug development. Gale EA Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214 [TBL] [Abstract][Full Text] [Related]
15. Troglitazone (CS-045): a new antidiabetic agent. Kaneko T Horm Metab Res; 1997 May; 29(5):203-13. PubMed ID: 9228204 [No Abstract] [Full Text] [Related]
16. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Baillie TA; Kassahun K Adv Exp Med Biol; 2001; 500():45-51. PubMed ID: 11764978 [No Abstract] [Full Text] [Related]
17. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Masubuchi Y Drug Metab Pharmacokinet; 2006 Oct; 21(5):347-56. PubMed ID: 17072088 [TBL] [Abstract][Full Text] [Related]
20. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Goldkind L; Laine L Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):213-20. PubMed ID: 16456879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]